During this educational program, PCSK9 inhibiting approaches in treating hypercholesterolemia and in preventing cardiovascular events are disscussed in three lectures.

This course consists of the following lectures:

• Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most? - Prof. Ph. Gabriel Steg, MD
• Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients? - Prof. Marc S. Sabatine, MD
• Targeting PCSK9: Expanding knowledge and targeting new frontiers - Prof. John Kastelein, MD

After watching the videos on PCSK9 inhibtion the learner should be able to:

• Describe the trial designs of the ODYSSEY Outcomes and FOURIER trials and understand how they differ
• Summarize the effect of PCSK9 inhibiting therapy in patients at high CV risk in terms of LDL-c lowering and CV outcomes
• Name patient subgroups that may benefit more from PCSK9 inhibiting treatment
• Recall the initial results on LDL-c lowering with the siRNA directed against PCSK9
• Understand what is novel about the approach of the PCSK9 inhibiting small molecule that is in development as an oral PCSK9 inhibitor

Expert faculty

• Prof. Ph. Gabriel Steg, MD - Paris, France
• Prof. Marc S. Sabatine, MD - Boston, MA, USA
• Prof. John Kastelein, MD - Amsterdam, the Netherlands

Target audience

This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating patients with hypercholesterolemia.

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by unrestricted educational grants from Amgen, Sanofi-Regeneron, The Medicines Company and Draupnir Bio.